Galapagos NV American Depositary Receipt
Galapagos NV American Depositary Receipt represents shares in Galapagos NV, a fully integrated biotechnology company headquartered in Mechelen, Belgium, and founded in 1999. The company focuses on transforming patient outcomes through life-changing science and innovation in immunology and oncology. It develops best-in-class therapies using multiple drug modalities, including small molecules, biologicals, and advanced cell therapies such as CAR-T products manufactured via a decentralized, point-of-care platform for rapid vein-to-vein delivery. Key therapeutic areas encompass immunology indications like rheumatoid arthritis, ulcerative colitis, axial spondyloarthritis, dermatomyositis, and systemic lupus erythematosus, alongside oncology programs targeting non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Galapagos synergizes internal expertise with external partnerships to accelerate discovery, development, and delivery of innovative medicines addressing high unmet medical needs. With operations spanning Europe and the United States, it maintains a deep pipeline and collaborates with leading organizations to pioneer next-generation treatments for serious diseases.
$29.90
-$0.03 (-0.10%)
EOD Oct 16, 2026
Margins and capital returns are both well above average: 45.08% operating margin, ROIC at 16.30%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 303.5% YoY with margins expanding 113.4pp.
Negative free cash flow of -€271M. The business is consuming cash, not generating it.
3.6x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€1.04B
▲ +303.5% YoY
Net Income (TTM)
€489M
▲ +333.1% YoY
Op. Margin
57.14%
▲ +113.4pp YoY
ROIC
16.30%
▲ +21.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€310M
▲ +32.5% YoY
Op. Cash Flow (TTM)
-€57M
▲ +14.1% YoY
Net Debt
-€2.99B
Net Cash Position
Cash & Equiv.
€3.00B
3Y CAGR: +66.4%
Continue Research
Is Galapagos NV American Depositary Receipt (GLPG) overvalued?
At a P/E of 3.6, Galapagos NV American Depositary Receipt (GLPG)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Galapagos NV American Depositary Receipt scores 61/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Galapagos NV American Depositary Receipt a high-quality business?+
Galapagos NV American Depositary Receipt scores 61 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 57.1% operating margin and a 16.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Galapagos NV American Depositary Receipt a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh GLPG's valuation and scores 61/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.